Table 1.
Baseline Characteristics of 59 MM Patients
| Baseline Characteristics | n (%) |
|---|---|
| Age | |
| Median (range), years | 67 (47–84) |
| <65 years | 26 (44.1) |
| ≥65–75 years | 27 (45.8) |
| >75 years | 6 (10.2) |
| Gender | |
| Male | 35 (59.3) |
| Female | 24 (40.7) |
| NDMM | 13 (22.0) |
| Continued to therapy | 33 (55.9) |
| Bortezomib PN-intolerant (≥PR) | 27 (45.8) |
| RRMM | 13 (22.0) |
| Relapse | 4 (6.8) |
| Refractory | 3 (5.1) |
| Relapse and refractory | 6 (10.2) |
| ECOG PS | |
| 0–1 | 12 (20.3) |
| 2 | 19 (32.2) |
| ≥3 | 28 (47.5) |
| ISS disease stage | |
| I | 8 (15.7) |
| II | 13 (22.0) |
| III | 38 (64.4) |
| R-ISS disease stage | |
| I | 6 (11.8) |
| II | 30 (50.8) |
| III | 23 (39.0) |
| Durie–Salmon stage | |
| I | 3(5.1) |
| II | 10(16.9) |
| III | 46 (78.0) |
| M-protein subtype IgG λ | 19 (32.2) |
| IgG | 32 (54.2) |
| IgA | 12 (20.3) |
| IgE | 1 (1.7) |
| IgG/A | 1 (1.7) |
| λ light chain | 11 (18.6) |
| κ light chain | 2 (3.4) |
| ClCr, mL/min | |
| <30 | 12 (20.30) |
| 30–<60 | 13 (22.0) |
| 60–<90 | 13 (22.0) |
| ≥90 | 21 (35.6) |
| IMWG myeloma frailty status | |
| Fit | 8 (13.6) |
| Intermediate | 30 (50.8) |
| Frail | 21 (35.6) |
| Cytogenetic profile | |
| Standard risk | 48 (81.4) |
| High riska | 11 (18.6) |
| Prior treatment (except NDMM) | |
| Median cycle of treatment (range) | 3 (1–14) |
| PI | 17 (37.0) |
| IMiD | 3 (6.5) |
| PI+IMiD | 26 (56.5) |
Note: aHigh-risk cytogenetic was defined as any of del17p, t (4; 14), or t (14; 16).
Abbreviations: NDMM, newly diagnosed multiple myeloma; RRMM, refractory/relapsed multiple myeloma; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; R-ISS, revised International Staging System; ClCr, creatinine clearance rate; PI, proteasome inhibitor; IMiD, immunomodulatory drug.